The Firm represented Diagnósticos da América S.A. (“DASA”) in connection with a primary follow-on offering of 196,857,674 of its common shares (the “Shares”), as well as 19,685,740 warrants which were delivered to the Shares subscribers, offered and allocated for each 10 Shares issued as part of the offering (the “Warrants”).
The offering raised R$1.7 billion in net proceeds to DASA. The Shares and the Warrants were offered to certain qualified institutional buyers under Rule 144A in the United States and to non-U.S. persons outside the United States in reliance upon Regulation S. DASA’s shares are traded on the B3 stock exchange under the ticker symbol “DASA3,” while the warrants are traded on the B3 stock exchange under the ticker symbol “DASA11.”
DASA operates an integrated healthcare network, providing their users with best-in-class healthcare care experience on a daily basis. DASA’s network of laboratories consists of more than 900 service units located in four of the five regions of Brazil, being present in 122 cities throughout 13 States and the Federal District. DASA also owns 15 hospitals strategically located in the four regions of Brazil, all of which have oncology centers.
The Simpson Thacher team included Grenfel S. Calheiros, Luiz Noronha, Winnie Y. Loureiro and João Felipe Rocha (Capital Markets); and Michael Mann and Daisy Dai (Tax).